of severe infections in critically ill patients, including those receiving continuous renal replacement therapy (CRRT). The objective of this study was to develop a population pharmacokinetic model of meropenem in critically ill patients undergoing CRRT.
Background
for >1 day for ≥20 h/day; and (iii) isolated or expected causative pathogen susceptible to meropenem. The guardians of all patients Meropenem is a carbapenem antibacterial with a wide spectrum provided written informed consent. Complete medical histories of activity, including Gram-positive, Gram-negative and anaerobwere obtained for all patients, and complete physical examinations ic microorganisms. It has shown clinical and bacteriological effiand laboratory reviews of serum chemistry and haematology cacy in the treatment of a wide range of serious infections in adults profiles were performed and reviewed before collection of samand children, and is prescribed for the treatment of infections in ples for pharmacokinetic analysis. The study was conducted in critically ill patients in intensive care due to its high degree of accordance with good clinical practice and was approved by the activity, its tolerability and its low incidence of toxicity. [1] medical ethical committees of the Santiago Apóstol Hospital Meropenem has linear pharmacokinetic properties over the (Vitoria-Gasteiz, Spain) and Doce de Octubre Hospital (Madrid, dose range of 0.25-2 g, with an elimination half-life of approxiSpain). mately 1 hour in healthy volunteers. [1, 2] Meropenem is eliminated by both metabolism and excretion. In healthy volunteers, 19-27%
Renal Replacement Therapy of a 1 g dose is excreted as a microbiologically inactive open β-lactam metabolite, [3] and up to 83% of the dose has been recovered All patients were undergoing CRRT, which has been defined as unaltered in the urine. [4] any extracorporeal blood purification therapy intended to substiMeropenem is commonly administered to critically ill patients.
tute for impaired renal function over an extended period of time The structural and pharmacokinetic characteristics of meropenem and applied for, or aimed at being applied for, 24 hours/day. [18] In (i.e. water solubility, relatively small molecular weight [383. 5 D] our study, patients were specifically treated with continuous veand low protein binding) allow for efficient removal of this drug novenous haemofiltration (CVVH, n = 10) or continuous venoveby continuous renal replacement therapy (CRRT). Hydrophilic nous haemodiafiltration (CVVHDF, n = 10). antimicrobials such as carbapenems are at higher risk of daily Vascular access was obtained with 13.5 FG dual lumen cathepharmacokinetic variations in critically ill patients. [5] Consequentters (Niagara, Bard Canada, Inc., Mississauga, Ontario, Canada). ly, they should be more closely monitored, and their dosages Haemodiafiltration machines (PRISMA, Hospal, Lyon, France; or should be streamlined according to the underlying diseases in MULTIFILTRATE, Fresenius Medical Care, Bad Homburg, Gerorder to prevent under-or overexposure, [5] to avoid treatment many) were used with polyacrylonitrile AN69 HF 0.9 m 2 memfailure and to improve survival. The pharmacokinetics of merbranes (PRISMA M100, Hospal) in 16 patients or polysulfone openem in critically ill patients undergoing CRRT have been membranes (Ultraflux AV600S, 1.4 m 2 Fresenius polysulfone ® , published previously, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] but a population pharmacokinetic anaFresenius Medical Care) in four patients. The blood flow was lysis has never been performed. Population pharmacokinetics seek maintained between 100 mL/min and 220 mL/min. In the CVto (i) identify the measurable pathophysiological factors that cause VHDF procedures, the dialysate flow rate was 500 mL/h or changes in the dose-concentration relationship; (ii) quantify the 1000 mL/h into the dialysate compartment of the filter in a blood extent of those changes; and (iii) estimate the magnitude of the flow countercurrent direction. The ultrafiltrate obtained was reunexplained variability in the patient population. [17] placed as clinically indicated at rates ranging from 800 mL/h to Considering the high pharmacokinetic variability in critically 2500 mL/h. Replacement fluids were delivered prefilter. ill patients and the lack of population pharmacokinetic information on meropenem in such patients, the purpose of this study was to Drug Administration, Sampling Procedure and develop a population pharmacokinetic model of meropenem in
Analytical Methods
critically ill patients undergoing CRRT with the objectives of Blood and dialysate-ultrafiltrate samples were obtained over quantifying the degree of interindividual variability (IIV) in the one or more dosing intervals at steady state after administration of model parameters and identifying the patient characteristics re-500 mg, 1000 mg or 2000 mg of meropenem every 6 or 8 hours by sponsible for IIV.
intravenous infusion. Blood samples (4 mL, using lithium heparin Methods as an anticoagulant) were obtained from a prefilter device immediately before dosing, at the end of the infusion, at 20, 30 and 45 minutes, and at 1, 3 and 6 hours after the beginning of the Study Design and Setting infusion. Another sample was collected 8 hours after the beginning A prospective, open-label study was conducted in intensive of the infusion in patients to whom meropenem was administered care unit patients undergoing CRRT. Twenty patients (15 males every 8 hours. Trough and peak samples were obtained on the and five females) meeting the following criteria were eligible for following day or days in some patients. Simultaneously, dialysateinclusion in the study: (i) age >18 years; (ii) treatment with CRRT ultrafiltrate samples (3 mL) were taken directly from the dialysate-ultrafiltrate device. Blood specimens were centrifuged within two nested models differing in one parameter is significant at the 1 hour for 10 minutes at 1500 × g at 4ºC. Plasma and dialysate-5% and 1% levels, respectively. Since some of the models that ultrafiltrate samples were immediately frozen at -20ºC. The samwere compared were not nested, -2LL was not used directly for ples were then stored at -80ºC within 1 week and analysed within comparative purposes, and the value of the Akaike Information 1 month.
Criteria (AIC), [22] computed as equation 1: Determination of meropenem concentrations in plasma and AIC = −2LL + 2 × Np dialysate-ultrafiltrate fluid was performed by validated [19, 20] highperformance liquid chromatography with a Waters apparatus (Wa-(Eq. 1) ters Corp., Milford, MA, USA) coupled to a spectophotometric where Np is the number of the parameters in the model, was used detector. [16] The method used for plasma samples consisted of instead. The model with the lowest value of the AIC, given that the protein precipitation with acetonitrile, followed by washing with precision of the model parameters and the data description were dichloromethane. The dialysate-ultrafiltrate samples did not readequate, was selected. quire any preparation. Separation was performed on a µBondapak Population model parameters were expressed as the corre-C18 (30 cm × 3.9 mm × 10 µm; Waters Corp.) with ultraviolet sponding estimate together with the %CV computed as the ratio detection (296 nm). The mobile phase contained acetate buffer/ between the standard error provided by NONMEM and the estiacetonitrile (95 : 5, v/v) and was delivered at 2 mL/min. The assay mate of the parameter multiplied by 100. The magnitude of IIV was linear over the concentration ranges of 0.25-100 µg/mL for was also expressed as the %CV. the plasma samples and 0.1-100 µg/mL for the dialysate-ultrafiltrate samples. The intra-and inter-day coefficients of variation
The model development process was performed in three steps. (CV) ranged from 0.67% to 9.64% for the plasma samples and First, a base population model without incorporating covariates from 0.31% to 10.64% for the dialysate-ultrafiltrate samples at the and capable of describing the data appropriately was selected. three concentrations tested (0.75 µg/mL, 10 µg/mL and 75 µg/mL Disposition of the total drug in plasma was modelled using comfor the plasma and 0.3 µg/mL, 5 µg/mL and 75 µg/mL for the partmental models parameterized in terms of the apparent volumes dialysate-ultrafiltrate). The bias at these concentrations ranged of distribution and total plasma and distribution clearances. The from 2.02% to 14.44% for the plasma samples and from 0.11% to concentrations of meropenem in dialysate-ultrafiltrate were mod-9.85% for the dialysate-ultrafiltrate fluid. The lower limit of elled as the product between the Cp and the sieving coefficient quantification was considered the lowest level included in the (Sc), a parameter to also be estimated and defined as the fraction of calibration curve (0.25 µg/mL in plasma and 0.10 µg/mL in the drug eliminated across the membrane during CRRT. The dialysate-ultrafiltrate), where the measures of the intra-day CV significance of the off-diagonal elements of the Ω variance-covariand bias were 11.69% and 10.10% for the plasma samples and ance matrix was also evaluated at this stage. 0.98% and 9.11% for the dialysate-ultrafiltrate samples. No inter-
The covariate model was built in the second step. Age, fering peaks were detected with the assay. bodyweight (BW), dialysate plus ultrafiltrate flow (FLOW), creatinine clearance (CL CR) and the unbound drug fraction in plasma Population Pharmacokinetic Data Analysis (fu) were the continuous covariates evaluated for significance. The type of membrane (MEMB; = 1 for AN69 or = 2 for polysulfone), All data, including the concentrations of meropenem in plasma CRRT (= 1 for CVVHDF or = 2 for CVVH) and patient type (1 for (C p ) and in dialysate-ultrafiltrate (C u ) from all of the patients septic or 2 for polytraumatized) were the categorical covariates participating in the study, were fitted simultaneously under studied. Table I lists the covariate information of the patients the population approach using the first-order conditional estimaincluded in the current study. The relationships between covariates tion (FOCE) method with INTERACTION implemented in and individual pharmacokinetic parameter estimates were first NONMEM version V software. [21] explored graphically. Each covariate was added individually to the IIV was modelled exponentially, and the residual variability for base model, and those covariates that showed a significant impact the two types of measurements (the plasma and dialysate-ultrafilwere then incorporated (starting with the covariate that led to the trate concentrations) was initially described with a combined error largest drop in -2LL) one at a time until the full covariate model model; however, if during the model selection process one of the was obtained. If an added covariate did not cause a significant components (the additive or the proportional) of the residual error decrease in -2LL, it was removed. This forward inclusion apmodel was negligible, it was deleted from the model. proach was followed by its reverse (backward elimination), whereSelection between models was based on the precision of paraby a covariate found not to be significant was dropped in favour of meter estimates, goodness-of-fit plots, and the minimum value of the simpler model. This procedure continued until no more the objective function [-2 × log(likelihood); -2LL] provided by covariates could be eliminated. During the forward inclusion and NONMEM. A difference of 3.84 and 6.63 points in -2LL between backward exclusion approaches, the levels of significance used were 5% and 1%, respectively. PE = × 100 P sim − P P The selected population model was evaluated in the third step (Eq. 2) using the visual predictive check [24] and parametric bootstrap. where Psim and P represent the parameter model estimate from a simulated dataset and the original dataset, respectively. The abso-
Visual Predictive Check
lute performance error (APE) was defined as the absolute value of the PE. Simulations of the meropenem plasma concentration-time profiles were performed from 1000 simulated individuals receivResults ing a 500-mg or 2000-mg intravenous infusion for 20 minutes every 6 hours using the final model and its model parameter Meropenem was well tolerated in all patients; no adverse estimates, including IIV. For each dose group, the concentrationreactions attributable to meropenem treatment were reported, intime profiles corresponding to the 5th, 50th and 95th quantiles cluding tubulointerstitial nephritis. were represented together with the corresponding observations.
The pharmacokinetic profiles were best described with a twocompartment model. The data supported the inclusion of IIV in
Parametric Bootstrap
total plasma clearance (CL), the apparent volume of distribution of One thousand datasets with the same characteristics as the the central compartment (V1) and the Sc. The off-diagonal eleoriginal dataset were simulated on the basis of the selected model, ments of the Ω variance-covariance matrix resulted in a nonand the model parameters were then re-estimated. Bias and precisignificant effect (p > 0.05). The additive and proportional elesion were calculated by computing the median performance error ments of the combined error models were needed for both the Cp (MPE) and the median of the absolute performance error (MAPE), and the Cu; however, the estimates of the residual variance differrespectively. For each simulation providing a successful minimied between the two types of observations. zation run, the performance error (PE) was calculated as equation
Among the examined covariates, age, BW, MEMB and CRRT 2:
did not show significant covariate effects (p > 0.05) on any of the pharmacokinetic parameters. During the forward covariate incluprofiles of meropenem administered as an intravenous infusion of sion approach, CLCR, FLOW, and the patient type were found to 500 mg or 2000 mg. It is clear that both covariates are likely to be significant for CL (p < 0.05). CL was described as the sum of have a clinical impact. the renal clearance (affected by CLCR and the patient type), nonDiscussion renal clearance (not affected by any of the explored covariates) and extracorporeal clearance (calculated as the product between
The objective of this analysis was to develop a population FLOW and the S c). In the case of the V1, the fu and the patient type pharmacokinetic model of meropenem in critically ill patients were the covariates exerting a significant effect (p < 0.05). The undergoing CRRT by using plasma and dialysate-ultrafiltrate confollowing equations describe CL and the V1 in the full model, centration data from 20 patients. Several previous studies have incorporating all of the covariates selected during the forward reported on the pharmacokinetics of meropenem in critically ill inclusion approach (equation 3): patients undergoing CRRT by using traditional pharmacokinetic analysis. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] In contrast, by using population pharmacokinetic methods, this study extends the analysis to address potentially important covariates in order to estimate their influence on pharmacokinetic parameters and the magnitude of the variability that could not be assessed in the other studies. A bibliographical search in MEDLINE and using the WINSPIRS computer system failed to
identify other studies of population pharmacokinetics of mer-(Eq. 3) openem in patients undergoing CRRT. Deletion from the full model of the fu and FLOW covariates did A two-compartment model was preferred to a one-compartnot elicit a significant increase in -2LL (p > 0.01). The parameter ment model, as it provided a much better fit when base models estimates of the final selected model, which incorporates the without incorporation of covariates were evaluated in the first step significant covariates CLCR and the patient type, are presented in of the model building. The precision of the parameter estimates in table II, where it can be observed that all parameters were estimated with adequate precision.
Inclusion of the selected covariates in the model decreased the degree of IIV, with respect to the basic model, from 150% to 38% in CL and from 85% to 45% in the V 1. The IIV associated with the Sc was 18%. The additive and proportional residual errors corresponding to the Cp were 0.22 mg/L and 21%, respectively, and those corresponding to the Cu were 0.15 mg/L and 25%, respectively.
The mean population estimate of CL was a linear function of CL CR in both groups of patients, with an intercept of 6.63 L/h and slopes of 0.063 and 0.72 for septic and polytraumatized patients, respectively. The V1 was also dependent on the patient type, with values of 15.7 L for septic patients and 69.5 L for polytraumatized patients. The population CL was 15 L/h, and the population apparent volume of distribution of the peripheral compartment was 19.8 L.
The goodness-of-fit plots presented in figure 1 , together with the results of the visual predictive check shown in figure 2 , confirmed graphically that the selected model was supported by data. The MPE and MAPE values obtained from 966 successful minimization runs were below 10% and 30% for most of the model parameters, with the exception of the IIV of CL (MPE = -17%) and θCLCR(septic) and the IIV of the Sc (MAPE = 46% and 41%, respectively). Figure 3 explores the impact of the two selected covariates, CLCR and the patient type, on the plasma concentration-time the selected structural model suggested that the model parameters urine. [4] However, the influence of CLCR differed between septic were estimated with reasonable precision. The goodness of fit was and polytraumatized patients. In this way, renal clearance of confirmed by the plots of population and individual model predicmeropenem varied extensively from septic patients to severely tions versus observations and weighted residuals versus time for polytraumatized patients. The V1 also differed between these two both the plasma data and the dialysate-ultrafiltrate data. When types of patients. possible, the comparison between the pharmacokinetic parameters Other studied covariates such as age, BW, FLOW, fu, MEMB obtained by the population analysis method and the traditional and CRRT were not included in the final model. However, there approach can serve as an indicator of the accuracy of the populashould probably be another covariate, not included in the protocol, tion pharmacokinetic models. In this study, the pharmacokinetic that would have allowed us to specify and determine why parameters were consistent with the values calculated by the meropenem showed different pharmacokinetics in septic and polytraditional approach previously published. [16] traumatized patients. In fact, polytraumatized patients received Population pharmacokinetics are a very useful instrument to large quantities of intravenous fluid during an extended treatment provide quantitative inspection of the influence of several pathoperiod, which could have resulted in an expanded extracellular physiological and clinical covariates on the pharmacokinetic procompartment, as occurs with other drugs. [25] [26] [27] [28] [29] [30] However, the file of drugs. In our study, CLCR was found to have a significant volumes of fluid administered in both groups of patients, among correlation with CL during the development of the covariate other possible parameters, were not included in the data collection model, which is in accordance with the established finding that up sheet when the study was designed. According to all of this, we to 83% of the administered dose of meropenem is recovered in the must emphasize the importance of the patient's clinical status in characterizing the pharmacokinetic profile of the drug in critically lus and viridans group streptococci is ≤0.5 mg/L, and the value for ill patients.
susceptible Streptococcus pneumoniae and Neisseria meningitidis is ≤0.25 mg/L. Our results ( figure 3) show that polytraumatized The potential clinical significance of the statistically-based selected covariates was studied by computer simulations. Figure 3 patients may not achieve adequate efficacy indexes to deal with shows the effects of CLCR on the typical population pharmacokinspecific infections, especially Enterobacteriaceae, Pseudomonas etic profiles of meropenem for each type of patient and under the and Staphylococcus, even after receiving high doses of mersame dosing schedule used in the current study. First, it appears openem. Septic patients with conserved renal function will probclear that sepsis and polytrauma have an important effect on the ably not achieve plasma drug concentrations above the MIC of pharmacokinetic characteristics of meropenem. Then, CLCR has a some pathogens during the entire dosing interval. In these cases, much greater impact on plasma disposition of meropenem in administration of meropenem as a continuous infusion would be septic patients than in polytraumatized patients.
recommendable for optimization of antimicrobial therapy when an These pharmacokinetic results emphasize that meropenem CL isolated or expected causative pathogen has an MIC of ≥4 mg/L. is higher in polytraumatized patients and in those with better renal Continuous infusion of other β-lactams, such as ceftazidime, [32] function. However, pharmacodynamic considerations should also has also been recommend in critically ill patients with severe acute be taken into account. For β-lactam antibacterial agents, the pharrenal failure undergoing CRRT. 
